🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We're starting to pack up 🧳! Follow us on Bluesky: bsky.app/profile/mainea…

Reduced GC dose in #ANCA vasculitis: Benjamin Terrier confirms PEXIVAS results in real life: no difference in death/ESKD. Larger composite criteria [see table] (that may be discussed) in favor of standard GC dose, especially for RTX patients and severe AKI ard.bmj.com/content/early/…

Results of the TAPIR trial: glucocorticoid discontinuation in GPA #ANCA vasculitis. ▶️ higher number of relapse at 6 months for the discontinuation group ▶️ but driven by minor relapses and by subgroup not treated but Rituximab. Peter Merkel #ACR24 acrabstracts.org/abstract/a-mul…

Brace yourself, next Vasculitis Workshop is coming! Key dates: ✅ Abstract submission: 28 March - 19 September 2025 ✅ Workshop dates: 21 - 25 February 2026

Infections affect >50% of #ANCA-associated #vasculitis patients, with risk factors including diabetes, ESKD, kidney/lung involvement and treatment (methylprednisolone pulses, CYC, PLEX). Main site: respiratory system. Early risk management is crucial. doi.org/10.1016/j.autr…

First AI-driven model for grading #ANCA-associated #glomerulonephritis lesions achieves 93% accuracy. Grad-CAM heatmaps align with pathologists’ focus, enhancing prognosis reliability. Bonus: the heatmaps look like colorful PET scans of glomeruli! kireports.org/article/S2468-…

This study (aacrjournals.org/cancerimmunolr…) shows that, in tumor-bearing mice, C5aR blockade boosts anti-PD1 efficacy by enhancing #antitumor immunity. Could these benefits translate to reducing long-term treatment-related adverse events in our #ANCA #vasculitis patients?

In #ANCA #vasculitis, 27% patients rated their health better or worse (≥ 20 PGA points) than their physicians did. This discordance highlights the need to address patients' perspectives to improve communication, shared decision-making, and care outcomes. pubmed.ncbi.nlm.nih.gov/39671122/

There is a need to account for "immortal time bias". Here, we show that the effect of immune-related adverse events of ICIs wane when doing so in patients with metastatic urothelial cancer (link.springer.com/content/pdf/10…). Target trial emulation approaches are gaining momentum!

Infection is the top cause of death in #ANCA-associated #vasculitis, mostly during remission. Death certificates misreport causes, linking EHRs improves accuracy. We need to reduce infection risks through better immunosuppressive therapies Zach Wallace sciencedirect.com/science/articl…

PEXIVAS post-hoc: no effect of reduced GC dose on kidney recovery in #ANCA #vasculitis. Faster kidney recovery with PLEX but no sustained effect beyond 3 months (better for subgroup 15-30?). Real PLEX effect vs convection effect? Balazs Odler Andreas Kronbichler kidney-international.org/article/S0085-…

🆕 #Obinutuzumab (Obi) in Lupus Nephritis: the REGENCY Trial Phase 3 RCT: Obi vs PBO 🫘 Pts w/ SLE nephritis Class III/IV ± 5 🎲 Randomized 1:1 to OBI v PBO (+MMF/steroids) 📊 Obi: ⇡rate of renal response #LupusNephritis #RheumTwitter #NephTwitter #Lupus

Kidney transplantation significantly improves survival in #ANCA-associated #vasculitis patients with end-stage kidney disease: 53% lower mortality risk. Let's improve access to #KidneyTransplant! Read more in our analysis from the french REIN registry doi.org/10.1016/j.ekir…

Kidney transplantation significantly improves survival in #ANCA-associated #vasculitis patients with end-stage kidney disease: 53% lower mortality risk. Our analysis from the french REIN registry ⬇️

US 🇺🇸 nephrologists, immunologists, pathologists (et al.): there is a place for each of you in France 🇫🇷 … and especially in Angers if you like #vasculitis! nature.com/articles/d4158…

This new study shifts the focus from anti-MPO IgG to IgM in #ANCA -associated #vasculitis. IgM autoantibodies not only trigger potent complement activation but also dominate the autoreactive memory B cell pool—revealing a new pathogenic paradigm. Potential implications ⬇️

Targeting endothelial ferroptosis protects kidneys in #ANCA -associated #vasculitis, while systemic inhibition increases inflammation). This is why cell-specific therapies should be prioritised over blanket treatments! Kidney International Adrian Schreiber doi.org/10.1016/j.kint…

Ex vivo #CRISPR-Cas9 knock out PR3 autoantigen in HSPCs prevents PR3-ANCA-driven neutrophil activation while preserving immune function. While aHSCT would still be required, this opens the door to sustained, drug-free remission in PR3 #ANCA #vasculitis! doi.org/10.1016/j.kint…

Our review on advances in the treatment of AAV is out now in NatRevRheumatol. It provides an update on currently used therapies and identified major innovations which will become relevant in the next couple of years! EUVAS nature.com/articles/s4158…

Outstanding review that outlines evolving #ANCA #vasculitis treatments: from B-cell therapies (obinutuzumab, CAR-T) and T-cell therapies to new comers (T-cell engagers, alternative-pathway inhibitors, antifibrotics, ANCA–antigen blockers). A must read! nature.com/articles/s4158…